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Background: Diabetes-induced organ damage is significantly associated with the activation of the renin-angiotensin
system (RAS). Recently, several studies have demonstrated a change in the RAS from an extracellular to an intracellular
system, in several cell types, in response to high ambient glucose levels. In cardiac myocytes, intracellular angiotensin
(ANG) II synthesis and actions are ACE and AT1 independent, respectively. However, a role of this system in
diabetes-induced organ damage is not clear.
Methods: To determine a role of the intracellular ANG II in diabetic cardiomyopathy, we induced diabetes using
streptozotocin in AT1a receptor deficient (AT1a-KO) mice to exclude any effects of extracellular ANG II. Further, diabetic
animals were treated with a renin inhibitor aliskiren, an ACE inhibitor benazeprilat, and an AT1 receptor blocker
valsartan.
Results: AT1a-KO mice developed significant diastolic and systolic dysfunction following 10 wks of diabetes, as
determined by echocardiography. All three drugs prevented the development of cardiac dysfunction in these animals,
without affecting blood pressure or glucose levels. A significant down regulation of components of the kallikrein-kinin
system (KKS) was observed in diabetic animals, which was largely prevented by benazeprilat and valsartan, while
aliskiren normalized kininogen expression.
Conclusions: These data indicated that the AT1a receptor, thus extracellular ANG II, are not required for the
development of diabetic cardiomyopathy. The KKS might contribute to the beneficial effects of benazeprilat and
valsartan in diabetic cardiomyopathy. A role of intracellular ANG II is suggested by the inhibitory effects of aliskiren,
which needs confirmation in future studies.
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Diabetic cardiomyopathy, defined as ventricular dysfunc-
tion that occurs independent of vascular or valvular pa-
thology, is a major morbidity factor in diabetic patients
[1,2]. Several mechanisms have been implicated in the de-
velopment of diabetic cardiomyopathy, including upregu-
lated oxidative stress, impaired calcium homeostasis, and
activation of the renin-angiotensin system (RAS) [3]. Cli-
nical and experimental studies have shown beneficial ef-
fects of RAS inhibitors in diabetes-induced organ damage
[4]. Currently, two classes of RAS inhibitors, angiotensin
type 1 receptor (AT1) blockers (ARBs) and ACE inhibitors,
are used in the clinic. However, cardiovascular morbidity
and mortality remain higher in diabetic patients on RAS
inhibitors compared to non-diabetics [5]. The latter obser-
vations have suggested the existence of residual risk in
patients, which might be related to insufficient RAS block-
ade, among other factors. With regard to insufficient RAS
blockade by ACE inhibitors and ARBs, we described an
intracellular cardiac RAS that is significantly upregulated
in diabetes [6-9]. An intracrine role of ANG II has also
been described by other investigators [10,11]. The intra-
cellular RAS in cardiac myocytes is not inhibited by ACE
inhibitors and ARBs, due to chymase-mediated synthesis
and AT1–independent actions of intracellular ANG II.
However, a renin inhibitor prevents both intra- and extra-
cellular ANG II synthesis. We reported that a renin inhibi-
tor was more effective than an ACE inhibitor or ARB in
preventing diabetes-induced cardiac superoxide produc-
tion, apoptosis and fibrosis [8], suggesting the intracellular
RAS as a possible residual risk factor in diabetes. To de-
termine whether the intracellular cardiac RAS has a role
in diabetes-induced cardiac dysfunction, we induced dia-
betes in AT1a receptor-deficient (AT1a-KO) mice by strep-
tozotocin (STZ). Our hypothesis was that in the absence
of extracellular ANG II-mediated effects in these animals,Figure 1 Study design. Twelve wk old male AT1a receptor knockout (AT1a
streptozotocin (50 mg/kg) for five days. After 2 wks, animals with blood glu
Echocardiographic measurements were taken in all groups at the beginnin
thereafter. Osmotic minipumps containing one of the drugs were implante
conclusion of the study (10 wks), blood pressure was measured by carotiddevelopment of cardiac dysfunction and prevention of the
latter by a renin inhibitor would indicate involvement of
intracellular ANG II in diabetic cardiomyopathy. We re-
port that AT1a-KO mice develop diabetes-induced cardiac
dysfunction, which is prevented by a renin inhibitor, as
well as by an ACE inhibitor and ARB.
Materials and methods
Animals
All animal protocols were approved by the Institutional
Animal Care and Use Committee and conformed to the
National Institutes of Health guidelines. Male AT1a-KO
mice were purchased from the Jackson Laboratory (stock
number 002682, Bar Harbor, Maine) and fed ad libitum.
At 12 wks of age, animals were randomized into control
and diabetic groups (Figure 1). Animals in the diabetic
group received STZ (50 mg kg-1 day-1; zanosar) intra-
peritoneally (i.p.) for 5 consecutive days, while those in
the control group received 0.1 M sodium citrate buffer
(pH 4.5). After 2 wks, mice with a blood glucose value
of ≥ 250 mg/dl were considered diabetic. The diabetic
group was divided into 5 subgroups (n = 10) that were
treated with either vehicle or RAS inhibitors, as follows: 1)
STZ + saline (STZ + Veh), 2) STZ +Aliskiren (20 mg/kg,
STZ +Alsk), 3) STZ + Benazeprilat (10 mg/kg, STZ +
Benz), 4) STZ + Valsartan (2 mg/kg, STZ + Vals), and
STZ + PD123319 (3 mg/kg) + Valsartan (2 mg/kg, STZ +
PD+Vals). The drug dosages were based on our pre-
viously published study [12]. Drugs were delivered by sub-
cutaneous osmotic minipumps (ALZET 1004, 0.11 μl/hr),
for 10 wks, with minipump replacement every 4 wks.
Echocardiography was performed at the beginning of dia-
betes (0 wk) and every 2 wks thereafter. At the end of the
study (10 wks of diabetes), the right carotid artery was
cannulated and arterial pressure measured under isoflur-
ane/oxygen (1.5/2%) anesthesia with a blood pressure-KO) mice were injected with either 0.1 M citrate buffer (pH 4.5) or
cose levels of ≥ 250 mg/dl were considered diabetic.
g (Before STZ), onset of diabetes (0 wk), and at two wk intervals
d subcutaneously at 0 wk and replaced after 4 and 8 wks. At the
artery cannulation and tissues were collected.
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have shown a close correlation between systolic blood
pressure measured under the conscious state and steady
isoflurane anesthesia and that the latter can be reliably
used to monitor changes in blood pressure in mice [13].
Hearts were immediately collected and processed for
either cardiac myocytes isolation or fixed with paraformal-
dehyde for staining. In addition to the 10 wks study, a
short study of one wk was performed to measure cardiac
RAS activation.
Echocardiographic measurements
Transthoracic echocardiography was performed using a
VisualSonics Vevo 2100 with a 35-MHz probe. Briefly,
mice were anesthetized with 3-5% isoflurane (with 2%
oxygen) that was reduced to 1.5% to maintain the heart
rate at about 450 beats per minute. The heart was im-
aged in the 2-dimensional, short-axis, and 4-chamber
view. Left ventricular (LV) fractional shortening (FS),
ejection fraction (EF), stroke volume (SV), cardiac out-
put (CO), LV internal dimension at end-diastole (LVI
Dd), LV internal dimension at end-systole (LVIDs), LV
posterior wall thickness at end-diastole (LVPWd), LV
posterior wall thickness at end-systole (LVPWs), inter-
ventricular septum thickness at end-diastole (IVSd),
intra-ventricular septum thickness at end-systole (IVSs),
isovolumic relaxation time (IVRT), isovolumic contrac-
tion time (IVCT), early diastolic (E’) and late diastolic
(A’) mitral annulus tissue Doppler velocities, and peak
velocity of early (E) and late (A) LV filling waves were
measured.
Isolation of adult mouse cardiomyocytes
Adult mouse cardiomyocytes were isolated using a
temperature-controlled (37°C) Langendorff ’s perfusion
system, as previously described with some modifications
[14]. Briefly, hearts were perfused with perfusion buffer
for 5 min, followed by digestion with collagenase II
(0.17% W/V, 330 U/mg, Worthington Biochemical Corp),
for 10 min, at a rate of 3 ml/min. After stopping digestion
with a serum- and calcium-containing buffer, cells were
washed with PBS and collected by centrifugation (180 rcf,
1 min). One portion of cardiac myocytes was snap frozen
in liquid nitrogen for protein analysis or ANG II ELISA
measurement, and the other was stored in RNAlater solu-
tion for RNA analysis.
Real-time PCR
Gene expression of angiotensinogen (AGT), renin, AT1a,
AT1b, tissue kallikrein, kininogen 2, prorenin receptor
(PRR), ACE2, and Mas was determined using TaqMan
assays (Applied Biosystems). RNA was extracted using
an RNeasy Fibrous Tissue Kit (Qiagen). cDNA was made
using a High Capacity cDNA Reverse Transcription Kit(Applied Biosystems). Real-time PCR was performed in
20 μl reaction containing cDNA, TaqMan Universal PCR
master mix, and 20X specific gene expression assay mix
(Applied Biosystems). Data were normalized to 18S
mRNA. Each sample was run in duplicate, and the thresh-
old cycle, ΔCt, was calculated as Ct (target gene) - Ct
(18S). The relative changes in target gene in different
treatment groups were determined by the formula 2-ΔΔ Ct,
where ΔΔ Ct =ΔCt (control) - ΔCt (treatment group).
The efficiency of AT1a and AT1b PCR was determined using
a 10-fold dilution series of mouse adrenal gland cDNA.
The slope of the standard curve was determined and the
efficiency calculated using the formula E = 10 (−1/slope) -1.
Western blot analysis
Protein expression of renin, ANG II Type 2 receptor
(AT2), and bradykinin Type 2 (B2) receptor was assessed
with the standard Western immunoblotting technique.
Briefly, cardiac myocytes were sonicated in ice-cold lysis
buffer (Cell Signaling) supplemented with protease and
phosphatase inhibitor cocktails (Roche Applied Science).
Homogenates were centrifuged at 16,000 g and protein
concentration in the supernatant was determined using
DC™ protein assay kit (BioRad). Equal amounts of cell
lysate (60 μg) or plasma (0.05 μl) were separated on
4-20% SDS-polyacrylamide gels (120 V, 1 hr) and trans-
ferred to nitrocellulose membranes (27 V, 2 hrs). Blots
were probed with anti-renin (Sigma-Aldrich), anti-AT2,
and anti-B2 receptor (Santa Cruz Biotechnology) anti-
bodies. Equal protein loading was confirmed by Ponceau
staining, because GAPDH and beta-actin levels in the
hearts of AT1a-KO mice were significantly affected by dia-
betes or the treatments (data not shown). Protein bands
were detected using secondary antibodies labeled with
infrared dye 680/800 and the enhanced Odyssey Infrared
Imaging System (LI-COR, Biosciences).
ANG II measurement
ANG II levels in isolated cardiac myocytes were measured
by a competitive quantitative ELISA, following extraction
with 1 M acetic acid and purification over a reverse phase
C18 column, as described previously [15]. Since the cardiac
myocyte isolation procedure involves perfusion of the heart,
enzymatic digestion, and washing of the dispersed myocytes
with PBS, the steps would wash-off extracellular ANG II;
ANG II measured this way represents intracellular ANG II.
The above intracellular ANG II method had previously
been validated by mass spectrometry and confocal micros-
copy [9]. ANG II data have been presented in terms of per
unit heart weight to be consistent with the literature.
Reactive oxygen species staining
Hearts were fixed in 4% paraformaldehyde and frozen in
O.C.T. compound (Tissue-Tek). Frozen sections (20 μm)
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Sigma-Aldrich), at 37°C, for 30 min in a humidified
chamber protected from light. Fluorescent images (60X)
were obtained with a Leica TCS SP5X confocal micro-
scope and analyzed using ImageJ. Mean DHE fluore-
scence was calculated by subtracting integrated density
of the background signal from the integrated density of
the fluorescent staining for 10 fields/heart, 5 hearts/
group, and normalized to control.Apoptosis
Hearts were fixed in 10% paraformaldehyde and paraffin
embedded. Paraffin embedded sections (5 μm) were incu-
bated at 60°C for 15 minutes, de-waxed, and rehydrated.
Apoptosis was detected using terminal deoxynucleotide
transferase-mediated dUTP nick-end labeling (TUNEL)
assay, according to the manufacturer’s instructions (In situ
Cell Death Detection Kit, Roche). Actin filaments and nu-
clei of cardiac myocytes were counterstained using Alexa
Fluor 546 phalloidin (Invitrogen) and DAPI, respectively.
Positively stained nuclei were counted from 6–12 sections
per heart and 3 hearts per treatment group.Statistical analysis
All data were expressed as the mean ± SEM. One-way
ANOVA with Tukey’s post hoc test or multiple compa-
risons using two-way ANOVA with the Bonferroni post
hoc test, where appropriate, were used for statistical
analysis (GraphPad). P <0.05 was considered statistically
significant.Figure 2 Activation of the renin-angiotensin system. Activity of
the RAS was measured in cardiac myocytes isolated from wild type
(A-C) and AT1a-KO (A, D-E) mice after 1 wk of diabetes. ANG II (A) was
extracted from cardiac myocytes and measured using a competitive
ELISA. Angiotensinogen (AGT, B and D) and renin (C and E) expression
was measured in control and diabetic (STZ) samples, by real-time
RT-PCR and normalized to 18S mRNA. Values are expressed as the fold
change compared to control ± SEM. *P < 0.05 vs. control.Results
Diabetes activates the cardiac intracellular RAS
We had previously demonstrated intracellular ANG II
synthesis in neonatal and adult cardiac myocytes follo-
wing stimulation with high glucose in vitro and in rat
hearts after one wk of diabetes [8,9]. In these studies, an
ARB, candesartan, was used to prevent uptake of extra-
cellular ANG II, to distinguish intracellularly synthesized
ANG II from extracellular ANG II internalized by cells.
To further confirm intracellular synthesis of ANG II and
activation of the RAS, we produced diabetes in AT1a-KO
and WT mice for one wk and measured ANG II levels
in cardiac myocytes isolated from control and diabetic
animals. As shown in Figure 2, a several fold increase in
intracellular ANG II levels was observed in both AT1a-
KO and WT diabetic mice, compared to non-diabetic
controls. Additionally, AGT and renin gene expression
was increased in cardiac myocytes of diabetic animals
compared to controls. These results demonstrated acti-
vation of the cardiac intracellular RAS by hyperglycemia
in AT1a-KO mice.Diabetes induces diastolic dysfunction in AT1a-KO mice,
which is prevented by aliskiren, benazeprilat, and
valsartan
Others and we have shown prevention of cardiac dys-
function by ARBs and ACE inhibitors in animal models
of diabetes [12]. To determine whether AT1a-KO mice
would develop diastolic dysfunction, we used echocar-
diography to monitor ventricular function of control and
diabetic mice for up to 10 wks following the onset of
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hibitor (aliskiren), ACE inhibitor (benazeprilat), and ARB
(valsartan) to determine whether these agents would have
a protective effect in the absence of AT1a receptor. Dia-
stolic function was evaluated by measuring the ratio of
mitral valve flow velocities (E/A ratio) and isovolumic re-
laxation time (IVRT). As shown in Figure 3C and D, the
E/A ratio was significantly lower at 8 and 10 wks of dia-
betes, compared to before STZ. Further, IVRT increased
significantly after 10 wks of diabetes (Figure 3E, only 10
wk data shown). Intriguingly, treatment with all three clas-
ses of RAS inhibitors, including an ARB, completely
prevented the progression of diastolic dysfunction. Bloc-
king AT2 receptor with PD123319 in the presence of val-
sartan reduced the protective effects of the latter on E/A
(Figure 3D), suggesting a beneficial role of AT2.
Diabetes induces systolic dysfunction in AT1a-KO mice,
which is prevented by aliskiren, benazeprilat, and
valsartan
In addition to diastolic dysfunction, we observed impair-
ment of systolic function in diabetic AT1a-KO mice, as
determined by measurement of EF and FS (Figure 4).
Similar to WT animals [12], systolic dysfunction in the
diabetic AT1a-KO animals manifested at 10 wks after theFigure 3 Measurement of diastolic function by echocardiography. Rep
and STZ + Veh mice at 10 wks of diabetes (A and B, respectively). Temporal re
implanted with saline minipumps (STZ + Veh), demonstrating development o
relaxation time (E) of Control, STZ + Veh, and those treated with aliskiren (STZ
PD123319 (STZ + Vals + PD); before STZ treatment and at 10 wks after becom
collect reliable (before STZ) data in this group. Values are expressed as the meestablishment of diabetes. All three RAS inhibitors pro-
tected the diabetic hearts from systolic impairment.
Combined treatment with AT1 and AT2 blockers re-
duced protection provided by the AT1 blocker alone.
Additional parameters of cardiac structure and function
Several other indices of cardiac structure and function, as
measured by echocardiography, are presented in Table 1.
There was no statistical difference in the heart rate among
groups at the time of echocardiography. Cardiac output
and stroke volume were reduced in diabetic mice com-
pared to controls, which were significantly improved in all
single treatment groups. The isovolumic contraction time
was increased in the diabetic group, indicative of systolic
dysfunction, as described above. Diastolic dysfunction was
further confirmed by a decrease in the mitral annulus tis-
sue Doppler velocities (E’/A’) in diabetic animals, which
was prevented in the treatment groups. Significantly, left
ventricular posterior wall thickness, the interventricular
septum thickness (IVS), and the left ventricular internal
dimension, measured in diastole, did not change over the
course of diabetes, indicating no change in cardiac struc-
ture. However, the IVS measured in systole decreased, the
significance of which is not known. The latter was pre-
vented by all three RAS inhibitors.resentative pulsed-wave Doppler images of Mitral valve flow of Control
cordings of Mitral valve flow velocity (E/A) in control and diabetic mice
f diastolic dysfunction (C). Mitral valve flow velocity (D) and isovolumic
+ Alsk), benazeprilat (STZ + Benz), valsartan (STZ + Vals), and valsartan +
ing diabetic. 2 wk values for STZ + Vals + PD are shown, as we could not
an ± SEM. *P < 0.05 vs. Control (C) or respective Before STZ (D and E).
Figure 4 Measurement of systolic function by echocardiography. Representative M-mode short axis views of Control and STZ + Veh mice at
10 wks of diabetes (A and B, respectively). Ejection fraction (C) and fractional shortening (D) of Control, STZ + Veh, STZ + Alsk, STZ + Benz, STZ + Vals,
and STZ + Vals + PD, before STZ treatment and at 10 wks after becoming diabetic. 2 wk values for STZ + Vals + PD are shown, as we could not obtain
reliable (before STZ) data in this group. Values are expressed as the mean ± SEM. *P < 0.05 vs. respective Before STZ. #P < 0.05 vs. Control (10wk).
Yong et al. Cardiovascular Diabetology 2013, 12:169 Page 6 of 13
http://www.cardiab.com/content/12/1/169Blood glucose levels and mean arterial pressure
Blood glucose levels were monitored biweekly and were
consistently elevated. After 10 wks, diabetic animals
exhibited elevated blood glucose levels (>500 mg/dl),
which were not lowered by aliskiren, benazeprilat, and
valsartan (Figure 5A). Mean arterial pressure (MAP) in
AT1a-KO mice did not change as a result of hypergly-
cemia (Figure 5B), which is consistent with other reports
in the STZ-induced model of diabetes [16]. Treatment
with any of the RAS inhibitors did not reduce blood
pressure, which corroborated previous reports of lack ofTable 1 Echocardiography measurements in control, diabetic
Control STZ + Veh STZ + Alsk
HR 477 ± 20 473 ± 12 456 ± 21
CO 24 ± 1.90 15.8 ± 0.62* 22.5 ± 1.66†
SV 52.8 ± 1.60 35.9 ± 1.60* 45.3 ± 2.40*†
IVCT 15.5 ± 0.60 17.9 ± 0.60* 15.2 ± 0.50†
LVPWd 0.93 ± 0.03 0.90 ± 0.02 0.89 ± 0.03
LVPWs 1.29 ± 0.07 1.15 ± 0.09 1.37 ± 0.02
IVSd 0.93 ± 0.03 0.87 ± 0.03 0.89 ± 0.03
IVSs 1.36 ± 0.05 0.96 ± 0.05* 1.38 ± 0.05†
LVIDd 3.91 ± 0.09 3.79 ± 0.10 3.42 ± 0.09*
LVIDs 2.83 ± 0.15 2.57 ± 0.13 2.34 ± 0.10*
E'/A' 0.90 ± 0.04 0.67 ± 0.06* 0.84 ± 0.04
For control group, n = 8; STZ + Veh, n = 9; STZ + Alsk, n = 8; STZ + Benz, n = 9; STZ + Val
(μl), IVCT = isovolumic contraction time (ms), LVPWd = left ventricular posterior wall thi
systole, IVSd = interventricular septum thickness in diastole (mm), IVSs = interventricula
diastole, LVIDs = left ventricular internal dimension in systole (mm), E’A’ =mitral annuluhypotensive effects of these agents at comparable thera-
peutic doses in the absence of hypertension [17,18].
These observations suggested that the therapeutic effect
of the RAS blockers on cardiac function were not
secondary to the changes in hyperglycemia or blood
pressure.
Aliskiren and valsartan prevent diabetes-induced
oxidative stress and apoptosis in the heart
Diabetic AT1a-KO mice showed a significant increase in
DHE staining, compared to control mice. As shown in(10 wks), and treatment groups
STZ + Benz STZ + Vals STZ + PD + Vals
452 ± 21 438 ± 13 447 ± 26
21.82 ± 1.98† 21.48 ± 1.87† 17.96 ± 0.84*
47.51 ± 3.10† 47.82 ± 3.20† 39.76 ± 1.70*
15.2 ± 0.20† 15.5 ± 0.70† 16.8 ± 1.40
0.94 ± 0.02 0.96 ± 0.04 1.15 ± 0.08†
1.34 ± 0.06 1.28 ± 0.03 1.27 ± 0.06
0.98 ± 0.02† 0.93 ± 0.03 0.81 ± 0.04
1.40 ± 0.03† 1.30 ± 0.05† 1.21 ± 0.06†
3.47 ± 0.14* 3.68 ± 0.12 3.72 ± 0.12
2.42 ± 0.18 2.61 ± 0.10 2.67 ± 0.13
0.80 ± 0.05 0.81 ± 0.02 0.76 ± 0.11
s, n = 7; STZ + Vals + PD, n = 7. CO= cardiac output (mls/min), SV = stroke volume
ckness in diastole (mm), LVPWs = left ventricular posterior wall thickness in
r septum thickness in systole, LVIDd = left ventricular internal dimension in
s tissue Doppler velocities. * = p < 0.05 vs. Control; † = p < 0.05 vs. STZ + Veh.
Figure 5 Measurement of blood glucose, mean arterial pressure, oxidative stress, and cardiac myocyte apoptosis. Blood glucose values
shown are from animals before injecting STZ and after 10 wks of diabetes in different groups (A). Mean arterial pressure (MAP) was calculated
from blood pressure values measured through carotid artery cannulation following 10 wks of diabetes (B). Apoptosis was measured by TUNEL
staining of heart sections and is represented as TUNEL positive nuclei as a percentage of total nuclei (C). Oxidative stress was measured by DHE
staining (D and E). The staining intensity was calculated from five images per heart, three hearts per group and normalized to the section area
(D). Representative images of DHE staining are shown (E). Values are expressed as the mean ± SEM. *P < 0.05 vs. before STZ or Control,
#P < 0.05 vs. STZ + Veh.
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abolished by aliskiren and valsartan; but, not by benaze-
prilat treatment. The number of apoptotic cells, detected
by TUNEL staining, increased significantly in the diabetic
heart (Figure 5C). The changes in apoptosis in diabetic
and treated hearts were consistent with the changes in the
oxidative stress. However, we did not observe an increase
in cardiac fibrosis or a change in cardiac structure, as
measured by LV posterior wall and interventricular
septum thickness using echocardiography (data not
shown). These results are consistent with our previous ob-
servations in WT mice [12].
Cardiac AT1b expression in AT1a-KO mice
To determine any potential functional compensation by
AT1b in AT1a-KO mice, we measured mRNA levels of
AT1b in cardiac myocytes from WT mice, which were
barely detectable with Ct values around 40. To compare
the expression of AT1a and AT1b, we determined the
efficiency of the two PCRs, which were 0.91 and 0.94,
respectively (Figure 6A and B). Comparatively, AT1b
expression was ~1/1316th of AT1a. In AT1a-KO mice,
AT1b was upregulated slightly but was still ~1/543th of
AT1a in WT mice (Figure 6C). Importantly, AT1b expres-
sion was reduced in diabetic AT1a-KO mice, comparedto non-diabetics. Renal mRNA levels of AT1b and AT1a
were about 3-fold higher than the hearts; however, AT1b
expression remained scarce in comparison to AT1a in
WT mice. There was a small increase in renal AT1b
expression in AT1a-KO mice, but it was ~700 fold lower
than renal AT1a in WT mice (Figure 6D).
Plasma renin levels are not changed following treatment
with RAS inhibitors
RAS inhibitors cause a reactive rise in plasma renin by
interfering with the negative feedback effects of ANG II
on kidneys via AT1 receptor [19]. Similarly, we had pre-
viously reported an increase in plasma renin following
RAS inhibition in WT mice [12]. To examine whether
levels of AT1b in AT1a-KO mice, though extremely low,
are sufficient to cause a physiological response; we per-
formed Western blot analysis of plasma samples, using
an antibody which recognizes both prorenin and renin.
As shown in Figure 7A, only prorenin was detected,
which was reduced in diabetic animals compared to con-
trols. None of the RAS inhibitors used in this study
upregulated plasma prorenin. These results indicated
that levels of renal AT1b were not sufficient to respond
to RAS inhibition in AT1a-KO mice; and by derivation,
cardiac AT1b receptor were also functionally irrelevant.
Figure 6 Relative expression of AT1a and AT1b in WT and AT1a-KO mice. Efficiency of the PCR for AT1a and AT1b was determined using serial
dilutions of mouse adrenal gland cDNA (A and B). Parallel lines of the amplification reactions demonstrate similar efficiency of both PCRs.
Expression of AT1a and AT1b was measured by real-time RT-PCR in cardiac myocytes (C) and kidneys (D) of wild type and AT1a-KO (control and
diabetic (STZ, 10 wk)) mice. Values are expressed as the fold change compared to control ± SEM. *P < 0.05 vs. control.
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AT1a-KO mice following hyperglycemia or treatment with
RAS inhibitors
Upregulation of the PRR in kidneys and hearts of diabetic
animals has been reported, which may contribute to the
pathological mechanism of tissue damage [20,21]. WeFigure 7 Plasma renin levels and prorenin receptor and AT2 expressio
determined by Western blot analysis and PRR (B) expression was measured
treated with different RAS inhibitors, after 10 wks of diabetes (C). Represen
change compared to control ± SEM. *P < 0.05 vs. control.determined mRNA and protein levels of the PRR in car-
diac myocytes isolated from control, diabetic, and diabetic
animals treated with RAS inhibitors. No significant change
in PRR expression was observed in any of these groups,
suggesting that the PRR may not have a role in diabetic
cardiomyopathy in AT1a-KO mice (Figure 7B, protein datan in cardiac myocytes. Plasma renin (A) and AT2 (C) levels were
by real-time RT-PCR, in control, diabetic (STZ + Veh), and diabetic mice
tative Western blot images are shown. Values are expressed as the fold
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sion did not change in diabetes or following treatment
with RAS inhibitors (Figure 7C).
Aliskiren, benazeprilat, and valsartan normalize the
kallikrein-kinin system in diabetic hearts
The kallikrein-kinin system (KKS) has been implicated in
the development of diabetic cardiomyopathy [22,23]; and
interaction between the KKS and the RAS at the level of
ACE is well established [24]. In the present study, mRNA
levels of tissue kallikrein and kininogen were reduced in
isolated cardiac myocytes from diabetic hearts. Treatment
with benazeprilat and valsartan reversed the effect of dia-
betes on these two genes, whereas aliskiren treatment only
normalized kininogen mRNA expression (Figure 8A and
B). Protein expression data is not presented, as available
antibodies did not recognize tissue isoforms of mouse
kallikrein and kininogen with certainty. Further, the pro-
tein expression of B2 receptor, which is responsible for the
cardioprotective actions of bradykinin, was significantly
diminished in diabetic hearts (Figure 8C). Benazeprilat
significantly normalized the protein expression of B2
receptor, whereas aliskiren and valsartan did not have any
effect. Together, these results suggest that part of theFigure 8 Expression of tissue kallikrein, kininogen, kinin B2 receptor,
(B), ACE2 (D), and Mas (E) in cardiac myocytes of control, STZ + Veh, STZ +
diabetes was measured by real-time RT-PCR and normalized to 18S mRNA.
(C). A representative Western blot image is shown. Values are expressed as
#P < 0.05 vs. STZ + Veh.beneficial effects of RAS inhibitors was mediated by the
KKS.
Effect on ACE2/Ang 1-7/Mas pathway
ACE2/Ang 1-7/Mas pathway represents a protective me-
chanism in the heart, which is downregulated in diabetes
(Figure 8D and E). We observed that the expression of
ACE2 was enhanced in all treatment groups except in the
STZ +Vals + PD group. A reduction in Mas expression in
diabetes was not reversed by any treatment.
Discussion
In this study, we determined a role of the intracellular car-
diac RAS in the development of diabetes-induced cardiac
dysfunction. We report three significant findings: 1) acti-
vation of the intracellular RAS, indicated by increased
intracellular levels of ANG II in the absence of AT1a-
mediated uptake; 2) development of cardiac dysfunction
in AT1a-KO mice, which is prevented by a renin inhibitor
and; 3) prevention of cardiac dysfunction by an ACE
inhibitor and ARB in AT1a-KO mice, possibly through
activation of the kallikrein-kinin system.
The basic premise of this study was the activation of
the intracellular cardiac RAS in diabetes. In our previousACE2, and Mas. mRNA expression of tissue kallikrein (A), kininogen
Alsk, STZ + Benz, STZ + Vals, and STZ + Vals + PD after 10 wks of
B2 receptor expression was measured by Western blot analysis
the fold change compared to control ± SEM. *P < 0.05 vs. control,
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was based on an increase in cellular ANG II levels, after
pharmacological blockade of ANG II uptake by cells
using an ARB [8,9]. Here we demonstrated activation of
the intracellular RAS in a genetic model of AT1a-defi-
ciency. We measured AGT and renin expression and
ANG II concentration in cardiac myocytes isolated from
AT1a-KO mice after one wk of diabetes. A significant
upregulation of AGT and renin expression was observed,
which was accompanied by a several fold increase in
ANG II levels in AT1a-KO mice. The increase in ANG II
levels was similar to that in WT mice (Figure 2). Intra-
cellular ANG II synthesis in cardiac myocytes of AT1a-
KO mice was likely due to retention of AGT and renin
inside cells in response to high ambient glucose levels,
as we had reported in neonatal rat ventricular myocytes
[9]. However, the intracellular site of synthesis and
mechanism of renin activation in cardiac myocytes are
not known. Since intracellular ANG II in AT1a-KO mice
could not have been due to cellular uptake, these obser-
vations clearly demonstrated activation of the intracellu-
lar RAS in the diabetic heart.
Rodents express two subtypes of AT1 receptor, AT1a
and AT1b. It may be argued that some of the observa-
tions in the current study could be related to AT1b re-
ceptor. Several studies have examined tissue-specific
expression of AT1a and AT1b in mice and rats. In rats,
one study reported solely AT1a expression in the heart,
another study detected very low AT1b expression, about
1/10th of AT1a expression [25,26]. However, in mice,
AT1b expression was detected only in the adrenal gland,
brain, and testis; not in the heart [27]. In another mouse
study, in which the AT1b coding exon was replaced with
the reporter gene lacZ, there was no detectable lacZ ex-
pression in kidneys and heart [28]. Consistent with these
studies, we observed extremely low levels of cardiac
myocyte AT1b expression, i.e., 1/1316th and 1/543th in
WT and AT1a-KO mice, respectively, as compared to
AT1a expression in WT mice. AT1b expression was de-
tectable because we performed PCR up to 40 cycles,
while routine protocols use only 30 cycles. Kidneys had
higher expression of AT1b compared to the heart; how-
ever, were not responsive to RAS inhibitors, as shown by
the lack of a reactive rise in renin expression. These ob-
servations suggested that the levels of AT1b in the heart
were not sufficient to be physiologically relevant. Func-
tional studies in AT1a-KO or AT1a-AT1b double knock-
out mice by other investigators also did not find any role
for AT1b in the heart [29,30]. Further, AT1b expression
was reduced in the diabetic group compared to controls,
indicating that AT1b did not contribute to diabetes-
induced cardiac dysfunction. To determine the role
of the AT2 receptor, we treated diabetic animals with
the AT2 antagonist PD123319, along with valsartan.Treatment with the AT2 blocker reduced the protective
effects of valsartan, suggesting that the AT2 receptor had
a beneficial role and was not involved in diabetes-
induced cardiac dysfunction.
Nuclear AT1 and AT2 receptors have been described
in cardiac myocytes, which respond to ANG II stimula-
tion by initiating nuclear signaling events [31]. Genetic
removal of AT1a and the lack of functional levels of
AT1b expression would indicate that AT1a-KO mice will
not have cardiac nuclear AT1 receptors. AT2 has a pro-
tective role, as discussed above. Thus, a role of the
known nuclear ANG II receptors in intracellular ANG
II-mediated diabetic cardiomyopathy is unlikely. Further
studies are required to understand the mechanism of
intracellular ANG II-induced diabetic cardiomyopathy.
Given that RAS inhibitors are cardioprotective in dia-
betes, the development of cardiac dysfunction in diabetic
AT1a-KO mice represents an important finding. A de-
crease in systolic and diastolic function and increase in
oxidative stress and apoptosis in the heart of diabetic ani-
mals was observed. The systolic and diastolic dysfunction
in AT1a-KO mice appeared similar to that we described in
WT animals [12]. The onset of cardiac dysfunction was
slightly delayed (E/A: 6 wks vs. 8 wks in WT vs. AT1a-KO
mice, respectively) and the degree of severity was less after
10 wks of diabetes in AT1a-KO mice (E/A: 1.11 vs. 1.24;
IVRT: 19.8 vs. 18.7 ms; EF: 47 vs. 52%; FS: 23 vs. 26%; in
WT vs. AT1a-KO mice, respectively). However, these dif-
ferences could be due to inter-experimental variation.
These observations suggested that the development of dia-
betic cardiomyopathy was independent of AT1a. A similar
observation was made regarding STZ-induced diabetic
nephropathy in AT1a-KO mice [20]. It was reported that
the AT1a deficiency delayed the onset of diabetes-induced
glomerulosclerosis and proteinuria; but, did not prevent
full development of these pathological endpoints [20].
Treatment with the ACE inhibitor imidapril partially pre-
vented diabetic nephropathy; these investigators did not
study the effect of an ARB. However, a handle region
peptide, that blocked binding of prorenin to the prorenin
receptor (PRR) and inhibited downstream signaling, com-
pletely prevented glomerulosclerosis and proteinuria.
Based on these observations, the investigators concluded
that an ANG II-independent mechanism contributed to
the development of diabetic nephropathy [20]. We ob-
served no change in PRR expression in cardiac myocytes
of diabetic AT1a-KO animals or following treatment with
RAS inhibitors, compared to non-diabetic controls, sug-
gesting that the PRR was not involved in cardiac dysfunc-
tion in AT1a-KO mice. We had previously observed
increased cardiac PRR in diabetes in WT mice [12]. Given
that PRR expression is increased in conditions that acti-
vate the RAS (low salt and hyperglycemia) and is
decreased by RAS inhibition, we believe that AT1 receptor
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this study. Further, development of diabetic cardiomyo-
pathy in AT1a-KO mice supported our hypothesis and
previous reports of AT1-independent actions of intracellu-
lar ANG II in the heart [8,15,32]. However, to confirm the
involvement of ANG II, we studied whether blocking
ANG II synthesis with a renin inhibitor would prevent
diabetes-induced cardiac dysfunction in AT1a-KO mice.
We also investigated whether an ACE inhibitor or ARB
would provide protection via non-RAS mechanisms, as
was suggested by our previous study in WT mice [12].
We observed that the renin inhibitor aliskiren com-
pletely protected animals from developing cardiac dys-
function up to 10 wks of diabetes. We have previously
reported that high glucose-induced intracellular ANG II
synthesis is both renin and chymase-dependent in cardiac
myocytes and renin and ACE-dependent in cardiac fibro-
blasts [9,33]. Aliskiren accumulates in tissues, including
cardiac myocytes and therefore inhibits renin-dependent
intracellular ANG II production [8,34,35]. We previously
reported that aliskiren was better than benazeprilat and
candesartan in reducing cardiac ANG II levels and pre-
venting diabetes-induced cardiac myocyte apoptosis, oxi-
dative stress, and cardiac fibrosis after one wk of diabetes
in rats [8]. In the current study, preservation of heart
function by aliskiren in AT1a-KO animals, suggested
the involvement of intracellular ANG II in diabetic
cardiomyopathy.
Significantly, benazeprilat and valsartan also showed
protective effects, similar to aliskiren, in AT1a-KO mice.
Regarding protection by the ACE inhibitor, it may be
argued that ACE-mediated ANG II synthesis in the cir-
culation or by cardiac fibroblasts had a role in cardiac
dysfunction. However, in the absence of AT1a receptor,
extracellular ANG II would be ineffective in the heart.
The latter argument also applies to any change in the
circulating RAS, as a result of AT1a deficiency or the
RAS inhibitor treatment. It has been reported that ACE
inhibitors also have cardioprotective effects through in-
hibition of kinin degradation [24,36]. Additionally, these
drugs enhance kinin B1 and B2 receptor function via
allosteric mechanisms that involve ACE and B2 receptor
heterodimerization and direct binding of ACE inhibitors
to B1 receptor [37]. Beneficial effects of kallikrein over-
expression and B2 receptor signaling, and detrimental
effects of B1 receptor-induced inflammation, have been
described in diabetic cardiomyopathy [23,38,39]. In this
study, benazeprilat normalized the expression of tissue
kallikrein, kininogen, and B2 receptor, which were im-
paired in diabetic animals, suggesting a role of the KKS
in cardioprotection by benazeprilat in AT1a-KO mice.
The blockade of the B2 receptor reduced the renal pro-
tective effects of the ACE inhibitor ramipril in db/db
mice, further supporting our conclusion [40].Particularly intriguing was the observation that the
AT1 receptor blocker valsartan was as effective as the
other two drugs, despite the lack of AT1a receptor in
these animals. As discussed above, the mouse heart does
not express physiologically relevant levels of AT1b; thus,
the protective effects of valsartan were likely mediated
via non-RAS mechanisms. Valsartan was recently shown
to markedly inhibit lipopolysaccharide-induced cytokine
production in macrophages and improve insulin resis-
tance in co-cultured adipocytes, via an unidentified AT1a
receptor-independent pathway [41]. Another ARB, losar-
tan, protected WT mice against myocardial ischemia-
reperfusion injury, which was not observed in kallikrein
gene-deficient mice, suggesting that the KKS was a
major determinant of the cardioprotective effects of
losartan [42]. Similarly, the inhibitory effects of valsartan
on ANG II-induced MAP and urinary sodium excretion
in healthy humans were shown to be mediated via the
B2 receptor [43]. We observed that valsartan signi-
ficantly increased mRNA expression of tissue kallikrein
and kininogen, which might have contributed to the
effects of valsartan in this study. To determine whether
these actions of valsartan on the KKS were mediated
through AT2 receptor, as suggested by some studies
[42,44], we measured AT2 expression and treated dia-
betic mice with the AT2 antagonist PD123319 in com-
bination with valsartan. No change in AT2 expression
was observed following diabetes or treatment with val-
sartan; however, we did observe reduced protection by
valsartan when used in combination with PD123319.
Further, activation of the KKS, with the exception of B2
receptor, was blunted with the co-treatment, suggesting
a contribution of AT2 in cardiac protection. It is note-
worthy that functional AT2 receptors on cardiac myocyte
nuclei have been demonstrated, which are accessible to
intracellular ANG II [31]. However, how valsartan would
modulate AT2 function in AT1a-KO mice is not clear.
Aliskiren treatment also increased kininogen levels; thus,
a partial contribution of the KKS in aliskiren-mediated
cardioprotection cannot be excluded [45]. ACE2 expres-
sion was increased in animals treated with all three RAS
inhibitors, suggesting increased Ang 1–7 generation; how-
ever, Mas expression was not rescued by these treatments.
Therefore, a role of the Ang 1-7/Mas axis, independently
or in concert with the KKS, in cardioprotection is not
clear.
Conclusions
In conclusion, we demonstrated an elevation of cardiac
intracellular ANG II and the development of diabetes-
induced cardiac dysfunction in AT1a-KO mice. All three
classes of RAS inhibitors protected the heart against dia-
betic cardiomyopathy. Whereas protection provided by a
renin inhibitor suggested the involvement of intracellular
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of the ACE inhibitor and ARB confounded the interpre-
tation. Two possibilities emerged from this study; either
the RAS did not have a significant role in the develop-
ment of diabetic cardiomyopathy, or if it did, then it was
likely via the intracellular RAS. Interestingly, our know-
ledge of the role of the RAS in diabetes-induced organ
damage is based entirely on pharmacological benefits
of RAS inhibitors. More studies utilizing genetic animal
models are required to determine precisely the role of
ANG II in diabetic tissue damage. If a role of intracellu-
lar ANG II in diabetic cardiomyopathy is established,
delineation of AT1-independent mechanisms of ANG II
would require substantial future research. In summary,
this study provides new insights into the role of the RAS
and RAS inhibitors in diabetic cardiomyopathy.
Limitations
This study focused on the role of cardiac intracellular
RAS in diabetic cardiomyopathy. Thus, isolated cardiac
myocytes, rather than whole hearts, were used to mea-
sure various molecular parameters, which severely li-
mited the amount of sample available for analysis. For
the latter reason, ANG II levels were not measured in
the treated groups. However, we had reported in wild
type mice and rats that AT1 receptor blockers and ACE
inhibitors did not significantly reduce intracellular ANG
II levels in cardiac myocytes from diabetic hearts. Only a
renin inhibitor prevented diabetes-induced ANG II for-
mation [8,12]. We did not expect different results in
AT1a-KO animals. Any change in the circulating ANG II
levels, as a result of the treatments with RAS inhibitors,
would not be of any consequence in the heart of AT1a-
KO animals. Another limitation of this study is that
gene expression data for some parameters described in
Figure 8 could not be confirmed by protein analysis due
to non-specific bands on Western blots that precluded
identification of protein-specific bands with certainty.
Regarding the mechanism of action of benazeprilat and
valsartan via the KKS, our data are consistent with the
literature; however, more studies will be required.
Finally, whereas our hypothesis of the role of intracellu-
lar ANG II in diabetic cardiomyopathy is strengthened
by the data presented, extended studies will be required
to unequivocally prove it.
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